Introduction
============

Previous meta-analyses and recent clinical trials have demonstrated that garlic supplements, including Kyolic aged garlic extract, are effective in reducing blood pressure in patients with uncontrolled hypertension, similar to first-line standard anti-hypertensive medications ([@b1-etm-0-0-8374]--[@b8-etm-0-0-8374]). Uncontrolled hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg and/or a diastolic blood pressure (DBP) ≥90 mmHg, including treated and untreated hypertensive patients, is prevalent in about a quarter (25%) of the adult population in Western countries ([@b9-etm-0-0-8374]). Up to 62% of patients on standard blood pressure medication experience adverse effects, such as fatigue, cold hands/feet, dry mouth, dizziness, headaches, muscular cramp/myalgia ([@b10-etm-0-0-8374]), thus highlighting the need for a more tolerable alternative therapeutic option.

A recent meta-analysis on the effects of garlic supplements on blood pressure, including 20 trials and \>900 participants, revealed a significant effect of garlic on blood pressure, with an average decrease in SBP of 8.6 mm and 6.1 mm in DBP in hypertensive subjects (n=14 trial arms, n=468 participants) ([@b4-etm-0-0-8374]).

To date, our group has conducted a number of clinical trials investigating the effects of Kyolic on blood pressure ([@b5-etm-0-0-8374]--[@b8-etm-0-0-8374]). Our first clinical trial including a pre-hypertensive group of adults (SBP ≥130 mmHg) revealed that Kyolic garlic significantly reduced blood pressure in the hypertensive subgroup (SBP ≥140 mmHg), but not in the normotensive subgroup (SBP \<140 mmHg) ([@b5-etm-0-0-8374]). This suggests that Kyolic aged garlic extract normalises blood pressure, in contrast to standard blood pressure medications, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta blockers (BBs), calcium channel blockers (CCBs), diuretics (Ds), which may sometimes lead to hypotension.

Our second dose-response trial revealed that a dose of 2 capsules/day of Kyolic aged garlic extract was sufficient to achieve an average blood pressure-lowering effect of 10 mmHg systolic and 5 mmHg diastolic, within 2--3 months ([@b6-etm-0-0-8374]). By contrast, 1 capsule per day was insufficient, whereas 4 capsules/day were not superior to 2 capsules/day. Two capsules of the High Potency Formula of Kyolic (Wagner/Nutralife available in Australia/New Zealand) contains 480 mg of concentrated aged garlic extract powder and 1.2 mg *S*-allyl cysteine (SAC), and are equivalent to 2 capsules of the Reserve Formula of Kyolic (Wakunaga of America available in the USA), containing 1.2 g of aged garlic extract powder and 1.2 mg of SAC.

In our third 'AGE at Heart' trial we found Kyolic to be effective in reducing peripheral blood pressure, as well as central blood pressure, central pulse pressure, pulse wave velocity and arterial stiffness ([@b7-etm-0-0-8374]). Central hemodynamic measures, such as central blood pressure, pulse wave velocity, pulse pressure and arterial stiffness, are regarded as more important predictors than peripheral blood pressure for cardiovascular disease risk ([@b11-etm-0-0-8374],[@b12-etm-0-0-8374]). Arterial stiffness, an indicator of the flexibility of the arteries, increases with age through the loss of intact elastin and collagen fibres in the arterial wall ([@b13-etm-0-0-8374],[@b14-etm-0-0-8374]), which also contributes to increased blood pressure ([@b15-etm-0-0-8374]). Kyolic aged garlic extract has been shown to be effective in reducing arterial stiffness, which in turn is related to better heart health and aerobic fitness, while the risk of cardiovascular disease is reduced ([@b7-etm-0-0-8374],[@b8-etm-0-0-8374],[@b12-etm-0-0-8374]).

While in the 'AGE at Heart' trial ([@b7-etm-0-0-8374]), the average blood pressure reduction observed in the garlic group (n=50) compared to the placebo (n=38) was statistically significant and comparable to that of previous studies ([@b5-etm-0-0-8374],[@b6-etm-0-0-8374]), in a subgroup of participants, blood pressure was not appreciably altered (SBP ≤5 mmHg, DBP ≤3 mmHg) over the 3 months course of the study (n=21 non-responders). We hypothesised that this non-response of blood pressure to garlic may be related to a deficiency in co-factors, including the B vitamins, and in particular folate, vitamin B2, vitamin B6 and vitamin B12, as these are essential co-factors in the mechanisms of action of garlic as regards the reduction of blood pressure ([@b16-etm-0-0-8374]).

Briefly, the mechanisms of action through which garlic influences blood pressure involve two main signalling pathways via nitric oxide (NO) and hydrogen sulphide (H~2~S) production ([@b16-etm-0-0-8374]). Garlic, a sulphur donor, provides an important component for the trans-sulphuration pathway, which is linked to the methylation pathway, with both requiring several co-factors, such as vitamin B12, folate, vitamin B2 and vitamin B6. In addition, known genetic variants for the cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE) enzymes influence the efficiency of H~2~S production, and thus are considered to play an important role in the susceptibility to developing hypertension, in conjunction with deficiencies in B vitamins. We have previously identified a potentially large proportion (80%) of healthy adults in Australia with sub-optimal vitamin B12 levels (\<500 pg/l) ([@b17-etm-0-0-8374]). Therefore, deficiencies in co-factors, such as vitamin B12, may explain the individual responsiveness of blood pressure to garlic observed in our clinical trials.

Furthermore, as high blood pressure has been linked to the dysbiosis of gut microbiota, both in animal and human studies, with a significant lower microbial richness and diversity in hypertensive subjects compared to normotensive subjects ([@b18-etm-0-0-8374]), we investigated the effects of Kyolic garlic on the microbiome in our most recent clinical study, the GarGIC trial ([@b8-etm-0-0-8374]). In general, a higher relative abundance/bacterial mass/microbial richness and a diversity of microbial species is associated with better health ([@b18-etm-0-0-8374]--[@b20-etm-0-0-8374]).

With its prebiotic properties, and the source of intracellular H~2~S ([@b16-etm-0-0-8374],[@b21-etm-0-0-8374]), garlic has the potential to modulate the gut microbiota ([@b22-etm-0-0-8374]), and to restore the microbiota biofilm and mucus production ([@b23-etm-0-0-8374]). The timeframe for changes to be observed in the composition of the gut microbiota with dietary supplementation is relatively short, as shown in a 4-week study of patients with irritable bowel syndrome taking probiotics daily ([@b24-etm-0-0-8374]). In addition, the consumption of probiotics has been shown to significantly reduce blood pressure, in particular in trials of \>8 weeks duration (meta-analysis of 9 RCTs involving 534 patients) ([@b25-etm-0-0-8374]).

In this study, we revise the meta-analyses on garlic and blood pressure in hypertensive subjects, including additional recent clinical trials. In addition, we review the role of B vitamins in the responsiveness of blood pressure to garlic, and summarise the effects of Kyolic aged garlic extract on arterial stiffness and gut microbiota.

Data and methods
================

For the meta-analysis of the effects of garlic on blood pressure in hypertensive subjects, we included randomised double-blind placebo-controlled trials on garlic for blood pressure with a minimum of 2 months duration, identified in previous meta-analyses: Specifically, Silagy and Neil, 1994 ([@b26-etm-0-0-8374]), Reinhart *et al*, 2008 ([@b2-etm-0-0-8374]), Ried *et al*, 2008 ([@b1-etm-0-0-8374]), Rohner *et al*, 2014 ([@b3-etm-0-0-8374]) and Ried, 2016 ([@b4-etm-0-0-8374]). We extended the search in Medline for trials published between 1955 and December, 2018 with no language restrictions, using the search terms 'garlic' AND 'blood pressure' OR 'hypertension'.

We included studies with adults with uncontrolled hypertension \[mean ± standard deviation (SD): SBP, ≥140±2 mmHg and/or DBP, ≥90±2 mmHg\], using garlic-only supplements, and reporting the mean SBP and/or DBP with SD or standard error (SE) at baseline and at end of the intervention. We included hypertensive subjects on an established plan of blood pressure medication, or subjects who were not taking any blood pressure medication at time of the trial. We excluded trials and trial arms with normotensive subjects, trials or trial arms using garlic-combination products, and trials with a very high attrition rate (loss to follow-up, \>30%).

For the meta-analysis, we entered the mean SBP and DBP into the Review Manager 5.3 program ([@b27-etm-0-0-8374]) using the inverse variance method and a random effects model. When blood pressure measurements were reported in \>1 position, the order of preference was as follows: i) Sitting; ii) standing; and iii) in the supine position. When both clinical and ambulatory blood pressure measurements were available, the order of preference was as follows: i) clinical; and ii) ambulatory. If results were reported for several periods of follow-up, we selected the longest follow-up from each study for comparison with the baseline. The outcomes were calculated as mean differences in SBP and DBP between the garlic and control groups at the final follow-up adjusted for baseline. We assessed heterogeneity by the I2 statistic, and overall significance with a P-value using the Review Manager program, as outlined in the Cochrane Handbook ([@b27-etm-0-0-8374]).

The risk of bias for each trial included the assessment of random sequence generation (selection bias), allocation concealment (selection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), blinding of participants and personnel (performance bias), and the blinding of outcome assessment (detection bias) ([@b27-etm-0-0-8374]).

Results
=======

A total of 12 trials involving 553 participants with hypertension were identified as meeting the inclusion criteria ([@b5-etm-0-0-8374]--[@b8-etm-0-0-8374],[@b28-etm-0-0-8374]--[@b34-etm-0-0-8374]), including 2 new trials ([@b7-etm-0-0-8374],[@b8-etm-0-0-8374]) that were not part of the most recently published meta-analyses ([@b4-etm-0-0-8374]). For trials with multiple intervention arms ([@b6-etm-0-0-8374],[@b34-etm-0-0-8374]), only the main arm was included in this updated meta-analysis, in order to avoid the double-counting of placebo groups. For trials with hypertensive and normotensive subgroups ([@b5-etm-0-0-8374],[@b7-etm-0-0-8374],[@b35-etm-0-0-8374]), only the hypertensive subgroup was included in this updated meta-analysis ([Table I](#tI-etm-0-0-8374){ref-type="table"}).

Not all participants of the trials included in the meta-analysis on systolic hypertension also suffered from diastolic hypertension. Eight out of the 12 trials involving 374 subjects met the inclusion criteria for the meta-analysis of diastolic hypertension ([@b7-etm-0-0-8374],[@b8-etm-0-0-8374],[@b28-etm-0-0-8374]--[@b30-etm-0-0-8374],[@b32-etm-0-0-8374],[@b34-etm-0-0-8374],[@b35-etm-0-0-8374]).

A further two trials published between 2013 and 2018, examining the effects of a garlic product on blood pressure, were excluded from the meta-analysis, as one trial testing patients with severe coronary artery disease did not include hypertensive subjects ([@b36-etm-0-0-8374]), and the other trial was not of sufficient quality ([@b37-etm-0-0-8374]). The latter trial of 80 participants and 4 groups investigated a combination of garlic and coriander seed powder (details of active ingredients or production were not provided), did not report on compliance or loss-to-follow-up, and provided no placebo supplement to the control group ([@b37-etm-0-0-8374]).

The meta-analysis of 12 trials involving adults with hypertension confirmed that the garlic supplements significantly lowered SBP by 8.32±1.93 mmHg (n=12 trials, n=553 participants, P\<0.00001), and DBP by 5.48±1.92 mmHg (n=8 trials, n=374 participants, P\<0.00001) ([Figs. 1](#f1-etm-0-0-8374){ref-type="fig"} and [2](#f2-etm-0-0-8374){ref-type="fig"}).

The included trials were of high quality with a minimal risk of bias ([Figs. 1](#f1-etm-0-0-8374){ref-type="fig"} and [2](#f2-etm-0-0-8374){ref-type="fig"}). An unclear risk of attrition bias was encountered in 2 trials ([@b28-etm-0-0-8374],[@b29-etm-0-0-8374]), which did not report on the loss to follow-up, one trial ([@b32-etm-0-0-8374]) reported 20% attrition in the garlic group and 11% in the placebo group, and another trial ([@b33-etm-0-0-8374]) reported 27% attrition in the garlic group, and none in the placebo group. No details on blood pressure measurements were reported in 2 trials ([@b32-etm-0-0-8374],[@b33-etm-0-0-8374]), leading to an unclear risk of detection bias, and no details on allocation concealment were reported in another trial ([@b30-etm-0-0-8374]). Resulting in an unclear risk of selection bias.

Eight out of the 12 trials used garlic powder, either Kwai manufactured in Germany (n=5) ([@b28-etm-0-0-8374]--[@b32-etm-0-0-8374]), Allicor from Russia (n=2) ([@b33-etm-0-0-8374],[@b34-etm-0-0-8374]), or a garlic powder manufactured in Japan (n=1) ([@b35-etm-0-0-8374]), while 4 trials investigated Kyolic aged garlic extract ([@b5-etm-0-0-8374]--[@b8-etm-0-0-8374]). Kyolic aged garlic extract powder is manufactured from organically grown garlic bulbs, which has undergone a 20-month aging process in 70% ethanol at room temperature. During the aging process, volatile sulphur components found in raw garlic, such as allicin, are chemically converted into stable and standardisable components, including the main vasoactive component, SAC ([@b38-etm-0-0-8374]--[@b40-etm-0-0-8374]).

In two of our clinical trials, Ried *et al*, 2010 ([@b5-etm-0-0-8374]) and Ried *et al*, 2013 ([@b6-etm-0-0-8374]), we used the 'Kyolic High Potency Formula' available in Australia and New Zealand (240 mg of concentrated aged garlic extract containing 600 µg SAC per capsule). In our 2 previous trials \[Ried *et al*, 2016 ([@b7-etm-0-0-8374]) and Ried *et al*, 2018 ([@b8-etm-0-0-8374])\], we used the 'Kyolic Reserve Formula' (600 mg of aged garlic extract powder containing 600 µg SAC per capsule). Both Kyolic formulas are comparable by dosage of the active ingredient SAC ([Table I](#tI-etm-0-0-8374){ref-type="table"}). The majority of trials used between 600--900 mg of garlic powder per day or 1,200 mg of Kyolic aged garlic extract for a median trial period of 12 weeks ([Table I](#tI-etm-0-0-8374){ref-type="table"}).

Discussion
==========

Our meta-analyses on the effects of garlic on hypertension, including 12 trials and 553 adults with high blood pressure, suggested that garlic supplements significantly lower SBP by an average of 8.3±1.9 mmHg and DBP (n=374) by 5.5±1.9 mmHg.

The average reduction in SBP of 8--10 mmHg induced by garlic supplements, alone or in combination with other blood pressure medications, is comparable to that of conventional standard blood pressure drug therapeutics, estimated to reduce the risk of cardiovascular events, such as heart attack, coronary artery disease, or stroke by 16--40% ([@b41-etm-0-0-8374],[@b42-etm-0-0-8374]).

In our clinical trials, in a proportion of participants, blood pressure was not appreciably altered (\>5 mmHg SBP and \>3 mmHg DBP; 30 or 17%, respectively), possibly owing to a suboptimal B vitamin status ([@b7-etm-0-0-8374],[@b8-etm-0-0-8374]). Some B vitamins are important co-factors in the mechanisms of action through which sulphur components in garlic are transformed into H~2~S, serving as signalling molecules for smooth muscle cell relaxation and vasodilation, leading to a reduction in blood pressure ([@b16-etm-0-0-8374],[@b43-etm-0-0-8374]).

In addition to the beneficial effects of garlic supplements on blood pressure, we, as well as others have found that Kyolic aged garlic extract is effective in rejuvenating the arteries, as evidenced by a reduction in pulse wave velocity ([@b7-etm-0-0-8374],[@b8-etm-0-0-8374],[@b12-etm-0-0-8374]). While arterial stiffness increases naturally with age by an average of 1.43 m/sec pulse wave velocity in 10 years ([@b13-etm-0-0-8374],[@b14-etm-0-0-8374]), our findings suggested that Kyolic aged garlic extract has the potential to reverse the ageing of the arteries and therefore, arterial stiffness by approximately 5 years, as evidenced by a mean reduction in pulse wave velocity by 0.7 m/sec within 3 months ([@b8-etm-0-0-8374]).

Furthermore, previous research suggests that garlic is effective in normalising blood cholesterol levels. A meta-analysis of 39 trials and 2,300 participants demonstrated an improvement in total cholesterol and low-density-lipoprotein (LDL) in adults with slightly elevated levels at baseline ([@b44-etm-0-0-8374]).

Moreover, Kyolic aged garlic extract has demonstrated to be able to normalise blood thickness. The blood thinning effect of garlic, of any type, is well known, decreasing the risk of blood clotting and thrombosis. Garlic is thought to interfere with platelet function by altering thromboxane production, preventing degranulation and interfering with the binding of fibrinogen with glycoprotein IIa/IIIa ([@b45-etm-0-0-8374]).

Importantly, Kyolic aged garlic extract does NOT increase the risk of bleeding, in contrast to other garlic products. A randomised double-blind placebo-controlled trial by Macan *et al* (2006) ([@b46-etm-0-0-8374]) administered warfarin (an anti-coagulant medication) to 52 patients at a dose of 10 g of liquid Kyolic aged garlic extract daily for 12 weeks, and assessed their increased risk of bleeding by the standard International Normalised Ratio (INR) test, finding no increased risk of bleeding in both the Kyolic garlic and the placebo group. Importantly, this trial demonstrated that Kyolic aged garlic extract differed from other garlic products, e.g., dietary garlic, and in particular raw garlic, and any warnings with regard to the increased risk of haemorrhaging are not warranted for Kyolic aged garlic extract. To the contrary, Kyolic aged garlic extract can be safely consumed before any planned surgery, and may even reduce the risk of thrombosis.

In addition to the beneficial effects of garlic on cardiovascular markers, our latest trial demonstrated a beneficial prebiotic effect on the microbiome by increasing microbial richness and microbial diversity, with the particular growth stimulation of the *Lactobacillus* and *Clostridia* species ([@b8-etm-0-0-8374]). *Lactobacillus* bacteria are generally regarded as beneficial ([@b47-etm-0-0-8374]), while common *Clostridia* species colonization in the gut has been found to activate innate immune-related genes in intestinal epithelial cells, and to prevent sensitization to food allergens in mice ([@b48-etm-0-0-8374],[@b49-etm-0-0-8374]).

In summary, this meta-analysis of 12 trials involving 553 adults with uncontrolled hypertension consolidated current evidence for garlic to be effective in reducing blood pressure by 8--10 mmHg systolic and by 5--6 mmHg diastolic, similarly to standard blood pressure medication. This decrease in blood pressure is associated with a 16--40% risk reduction of cardiovascular events, such as heart attack and stroke. The B vitamin status is an important factor for the responsiveness of high blood pressure to garlic in each individual. Kyolic aged garlic extract in particular is highly tolerable, and can safely be consumed, in addition to other standard blood pressure medication.

Latest research has provided new evidence for Kyolic aged garlic extract to improve central haemodynamic measures, including central blood pressure and pulse pressure, and pulse wave velocity, a measure for arterial stiffness, regarded as important predictors for cardiovascular disease. Kyolic aged garlic extract has the potential to reverse the ageing of the arteries and therefore, arterial stiffness by approximately 5 years, as evidenced by a mean reduction in pulse wave velocity by 0.7 m/sec within 3 months.

In conjunction with the normalising effects of Kyolic aged garlic extract on blood pressure, cholesterol levels and blood stickiness, Kyolic aged garlic extract provides beneficial effects on several levels important for cardiovascular health. Furthermore, prebiotic Kyolic aged garlic extract improves microbial richness and diversity in the gut, with a marked increase in the numbers of beneficial and immune-stimulating bacteria, such as *Lactobacillus* and *Clostridia* species, within a 3-month period.

Further larger and longer-term studies are warranted to assess the potential of Kyolic aged garlic extract on the gut microbiota. Moreover, it would be of interest to explore the responsiveness of high blood pressure to aged garlic extract in each individual, by investigating underlying dietary and genetic factors, such as vitamin B6 and folate levels, in addition to vitamin B12.
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###### 

Characteristics of trials included in the meta-analysis of garlic on blood pressure in hypertensives (SBP ≥140 mmHg, DBP ≥90 mmHg at baseline).

  Author/(Refs.), year                                No. of subjects (garlic/control group)   Garlic type   Brand                   Country of manufacture   Dosage (mg/day)   Dosage of active ingredient per day   Duration (weeks)   Garlic Baseline mean SBP/DBP (mmHg)   Control Baseline mean SBP/DBP (mmHg)
  --------------------------------------------------- ---------------------------------------- ------------- ----------------------- ------------------------ ----------------- ------------------------------------- ------------------ ------------------------------------- --------------------------------------
  Kandziora *et al* ([@b28-etm-0-0-8374]), 1988       20/20                                    GP            Kwai                    Germany                  600               7.8 mg alliin                         12                 174/99                                175/98
  Auer *et al* ([@b29-etm-0-0-8374]), 1990            24/23                                    GP            Kwai                    Germany                  600               7.8 mg alliin                         12                 171/102                               161/97
  Vorberg and Schneider ([@b30-etm-0-0-8374]), 1990   20/20                                    GP            Kwai                    Germany                  900               11.7 mg alliin                        16                 144.5/91                              144/88
  Holzgartner *et al* ([@b31-etm-0-0-8374]), 1992     47/47                                    GP            Kwai                    Germany                  900               11.7 mg alliin                        12                 143/83                                141/82
  Santos and Gruenwald ([@b32-etm-0-0-8374]), 1993    25/27                                    GP            Kwai                    Germany                  900               11.7 mg alliin                        24                 143/89                                144/89
  Sobenin *et al* ([@b33-etm-0-0-8374]), 2008         23/19                                    GP            Allicor                 Russia                   600               7.8 mg allicin pt                     12                 143/89                                140/88
  Sobenin *et al* ([@b34-etm-0-0-8374]), 2009         G2: 18/20                                GP            Allicor                 Russia                   2400              31.2 mg allicin                       8                  153/95                                150/94
  Ried *et al* ([@b5-etm-0-0-8374]), 2010             HT: 6/10                                 AGE           Kyolic High Potency     USA for Australia/NZ     960 (4 caps)      2.4 mg SAC                            12                 135/74                                141/76
  Ried *et al* ([@b6-etm-0-0-8374]), 2013             G2: 20/17                                AGE           Kyolic High Potency     USA for Australia/NZ     480 (2 caps)      1.2 mg SAC                            12                 149/76                                149/76
  Nakasone *et al* ([@b35-etm-0-0-8374]), 2013        HT: 23/24                                GP~jpn~       Dentou ninniku ranwo™   Japan                    188               NR                                    12                 HT: 142/91                            HT: 142/92
  Ried *et al* ([@b7-etm-0-0-8374]), 2016             HT: 38/26                                AGE           Kyolic Reserve          USA                      1200 (2 caps)     1.2 mg SAC                            12                 HT: 154/96                            HT: 146/93
  Ried *et al* ([@b8-etm-0-0-8374]), 2018             23/26                                    AGE           Kyolic Reserve          USA                      1200 (2 caps)     1.2 mg SAC                            12                 153/93                                144/90

AGE, aged garlic extract; GP, garlic powder; GP~jpn~, Japanese garlic powder containing egg yolk; G2, main garlic group, P, placebo group; HT, hypertensive subgroup; RG, raw garlic; mg; milligram; mg/dl, milligram per decilitre; mmHg, millimetre of mercury; NA, not applicable; NR, not reported; NZ, New Zealand; pt, potential; SAC, S-allylcysteine; SBP/DBP, systolic/diastolic blood pressure.
